Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; Nicolaus Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro; International Myeloma Working Group

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Standard

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. / Kyle, R A; Durie, B G M; Rajkumar, S V; Landgren, O; Blade, J; Merlini, G; Kröger, Nicolaus; Einsele, H; Vesole, D H; Dimopoulos, M; San Miguel, J; Avet-Loiseau, H; Hajek, R; Chen, W M; Anderson, K C; Ludwig, H; Sonneveld, P; Pavlovsky, S; Palumbo, A; Richardson, P G; Barlogie, B; Greipp, P; Vescio, R; Turesson, I; Westin, J; Boccadoro, M; Group, International Myeloma Working.

in: LEUKEMIA, Jahrgang 24, Nr. 6, 6, 2010, S. 1121-1127.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kyle, RA, Durie, BGM, Rajkumar, SV, Landgren, O, Blade, J, Merlini, G, Kröger, N, Einsele, H, Vesole, DH, Dimopoulos, M, San Miguel, J, Avet-Loiseau, H, Hajek, R, Chen, WM, Anderson, KC, Ludwig, H, Sonneveld, P, Pavlovsky, S, Palumbo, A, Richardson, PG, Barlogie, B, Greipp, P, Vescio, R, Turesson, I, Westin, J, Boccadoro, M & Group, IMW 2010, 'Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.', LEUKEMIA, Jg. 24, Nr. 6, 6, S. 1121-1127. <http://www.ncbi.nlm.nih.gov/pubmed/20410922?dopt=Citation>

APA

Kyle, R. A., Durie, B. G. M., Rajkumar, S. V., Landgren, O., Blade, J., Merlini, G., Kröger, N., Einsele, H., Vesole, D. H., Dimopoulos, M., San Miguel, J., Avet-Loiseau, H., Hajek, R., Chen, W. M., Anderson, K. C., Ludwig, H., Sonneveld, P., Pavlovsky, S., Palumbo, A., ... Group, I. M. W. (2010). Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. LEUKEMIA, 24(6), 1121-1127. [6]. http://www.ncbi.nlm.nih.gov/pubmed/20410922?dopt=Citation

Vancouver

Kyle RA, Durie BGM, Rajkumar SV, Landgren O, Blade J, Merlini G et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. LEUKEMIA. 2010;24(6):1121-1127. 6.

Bibtex

@article{309472653d62453292ba4a306993acc9,

title = "Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.",

abstract = "Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein",

author = "Kyle, {R A} and Durie, {B G M} and Rajkumar, {S V} and O Landgren and J Blade and G Merlini and Nicolaus Kr{\"o}ger and H Einsele and Vesole, {D H} and M Dimopoulos and {San Miguel}, J and H Avet-Loiseau and R Hajek and Chen, {W M} and Anderson, {K C} and H Ludwig and P Sonneveld and S Pavlovsky and A Palumbo and Richardson, {P G} and B Barlogie and P Greipp and R Vescio and I Turesson and J Westin and M Boccadoro and Group, {International Myeloma Working}",

year = "2010",

language = "Deutsch",

volume = "24",

pages = "1121--1127",

journal = "LEUKEMIA",

issn = "0887-6924",

publisher = "NATURE PUBLISHING GROUP",

number = "6",

}

RIS

TY - JOUR

T1 - Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

AU - Kyle, R A

AU - Durie, B G M

AU - Rajkumar, S V

AU - Landgren, O

AU - Blade, J

AU - Merlini, G

AU - Kröger, Nicolaus

AU - Einsele, H

AU - Vesole, D H

AU - Dimopoulos, M

AU - San Miguel, J

AU - Avet-Loiseau, H

AU - Hajek, R

AU - Chen, W M

AU - Anderson, K C

AU - Ludwig, H

AU - Sonneveld, P

AU - Pavlovsky, S

AU - Palumbo, A

AU - Richardson, P G

AU - Barlogie, B

AU - Greipp, P

AU - Vescio, R

AU - Turesson, I

AU - Westin, J

AU - Boccadoro, M

AU - Group, International Myeloma Working

PY - 2010

Y1 - 2010

N2 - Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein

AB - Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein

M3 - SCORING: Zeitschriftenaufsatz

VL - 24

SP - 1121

EP - 1127

JO - LEUKEMIA

JF - LEUKEMIA

SN - 0887-6924

IS - 6

M1 - 6

ER -